Fatigue is not associated with raised inflammatory markers in multiple sclerosis

Neurology

Volumn 57, Issue 4, 2001, Pages 676-681

  Giovannoni, Gavin ^a   Thompson, Alan J ^a   Miller, David H ^a   Thompson, Edward J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; NEOPTERIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FATIGUE; FEMALE; HUMAN; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0035964335     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.4.676     Document Type: Article

References (39)

1. Symptomatic fatigue in multiple sclerosis
2. Fatigue in multiple sclerosis
3. Modalities of fatigue in multiple sclerosis: Correlation with clinical and biological factors
4. Establishing a physiological basis to multiple sclerosis related fatigue - A case report
5. Fatigue in multiple sclerosis compared with chronic fatigue syndrome: A quantitative assessment
6. An openlabelled clinical and electrophysiological study of 3,4-diaminopyridine in the treatment of fatigue in multiple sclerosis
7. Sleep disturbance, depression, and lesion site in patients with multiple sclerosis
8. The nature of fatigue in multiple sclerosis
9. Fatigue in multiple sclerosis: Relationship to depression, disability, and disease pattern
10. Cytokine correlates of fatigue in multiple sclerosis
11. MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue
12. Fatigue in multiple sclerosis: Interrelations between fatigue complaints, cerebral MRI abnormalities and neurological disability
13. Fatigue in multiple sclerosis: Cross-sectional correlation with brain MRI findings in 71 patients
14. Fatigue and magnetic resonance imaging activity in multiple sclerosis
15. Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis
16. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
17. Major differences in the dynamics of primary and secondary progressive multiple sclerosis
18. Time dependence of urinary neopterin, a marker of cellular immune activity
19. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
20. Cognitive behaviour therapy in the chronic fatigue syndrome
21. Follow up of patients with fatigue presenting to an infectious disease clinic
22. The fatigue severity scale applied to patients with multiple sclerosis and systemic lupus erythematosus
23. Development of a fatigue scale
24. The hospital anxiety and depression scale
25. Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis
26. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases
27. Soluble E-selectin in multiple sclerosis: Raised concentrations in patients with primary progressive disease
28. Longitudinal study of soluble adhesion molecules in multiple sclerosis: Correlation with gadolinium enhanced magnetic resonance imaging
29. Statistics and ethics in medical research: III. How large a sample?
30. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly
31. Interleukin-1 alpha administered after autologous transplantation: A phase I/II clinical trial
32. Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: Results of a phase II study
33. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
34. Serum interleukin-2 and soluble interleukin-2-receptor in patients with multiple sclerosis who are experiencing severe fatigue
35. Primary progressive multiple sclerosis
36. A comparison of the pathology of primary and secondary progressive multiple sclerosis
37. Distinct patterns of multiple sclerosis pathology indicate heterogeneity on pathogenesis
38. The persistence of fatigue in chronic fatigue syndrome and multiple sclerosis: Development of a model
39. The measurement of fatigue in patients with multiple sclerosis - A multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects